Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in mean Total Improvement Score (TIS) over placebo at Week 52. Improvements were sustained from Week 4 onward, even through steroid tapering.
In IMNM, the primary endpoint was met with a 14.8-point improvement over placebo, while DM showed a similar 14.5-point benefit, though statistical significance was missed in that smaller cohort. On August 17, William Blair noted that the results boosted confidence in Vyvgart’s path in DM, sending ARGX shares up 15% to an all-time high. On August 18, RBC Capital raised its price target on Argenx to $1,100 from $1,025, calling the IMNM data a “slam dunk” and projecting rapid commercial uptake given the 20,000 U.S. patient population.
Financial Performance: Scale vs. Regional Licensing
argenx SE (NASDAQ:ARGX) and Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) share clinical success through an exclusive licensing agreement covering Greater China, but their financial profiles remain significantly different in scale and profitability. ARGX delivered blockbuster Q2 2026 results driven by strong global VYVGART momentum, with net product sales reaching $1.516 billion, up 60% year over year. Total operating income reached $1.542 billion, resulting in operating profit of $494 million and net income of $472 million. The company also maintained a strong balance sheet with $5.2 billion in cash and current financial assets.
ZLAB, by contrast, continues to operate as a developing commercial partner with substantially higher cash-burn requirements. Q2 2026 revenue totaled $106.3 million, down 3% year over year, while net product revenue reached $105.8 million. Rising R&D expenses of $61.8 million and SG&A expenses of $72.9 million contributed to an operating loss of $76.5 million and a net loss of $50.8 million. Zai Lab ended the quarter with $717.5 million in cash and short-term investments, highlighting the substantial financial gap between the two partners.
Bull and Bear Cases
Argenx’s bull case is supported by VYVGART’s growing global presence across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and autoimmune myositis. Its $5.2 billion liquidity position provides substantial financial capacity to expand into additional FcRn-mediated indications without significant dilution risk. However, the bear case centers on the company’s heavy reliance on VYVGART as its primary commercial growth engine, leaving the stock vulnerable to FDA delays or regulatory pushback surrounding separate trials for dermatomyositis (DM).
Zai Lab’s bull case is driven by its strong regional footprint in Greater China and an expanding portfolio that includes VYVGART, KarXT, and TIVDAK. Sequential revenue growth of 11% indicates improving commercial stability as the company scales its product portfolio. On the downside, Zai Lab continues to face persistent losses, including a $50.8 million net loss in Q2, while established products such as ZEJULA face commercial pressure from increasing generic competition in China.
Insider Monkey’s Hedge Fund Data Analysis
Institutional sentiment heading into 2026 showed moderate institutional trimming for both names. Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) held 14 hedge fund positions in Q1 2026 (down from 17 in Q4 2025), with RA Capital Management holding shares worth $109.1 million and ADAR1 Capital Management increasing its stake by 137%.
argenx SE (NASDAQ:ARGX) saw 42 hedge fund holdings in Q1 2026 (down from 48 in Q4 2025), though heavily backed by major funds like VenBio Select Advisor (shares worth $927.8 million) and Citadel Investment Group (shares worth $197.1 million).
Conclusion & What to Watch Next
Investors should watch whether the FDA requires an additional, standalone Phase 3 trial for Vyvgart in dermatomyositis, as well as regulatory submission timelines in both the U.S. and Greater China. Furthermore, monitor Zai Lab’s commercial execution on its newer launches to curb ongoing operating losses.
While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
